• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

IUD Use: Does Levonorgestrel Dose in IUDs impact Psychotropic Drug Use?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Some studies have found an association between levonorgestrel (LNG) IUDs and depression, and antidepressant and anxiolytic use
  • Previous studies focused on IUDs containing 52 mg of LNG
  • Roland et al. (JAMA, 2022) assessed whether LNG dose was related to use of psychotropic medications

METHODS:

  • Matched-cohort study
  • Population
    • 13 to 40 years
    • No psychotropic drugs in the previous year
    • No LNG IUD use in the 6 years prior to 2019
  • Exposures
    • 52-mg LNG IUD
    • 19.5-mg LNG IUD
  • Study design
    • Individuals in the study were matched 1:1 for
      • Age (±3 years)
      • Gravidity in the 10 years prior to the study
      • Month of device dispensation (±3 months)
      • Physician specialty
    • Logistic regression was used to calculate the odds ratio (OR)
    • Adjustments: Sociodemographic characteristics | Childbirth history | Medical history | Matching variables
  • Primary outcome
    • 2 or more prescriptions for anxiolytics, hypnotics, and/or antidepressants within 2 years after device insertion

RESULTS:

  • 52-mg LNG IUD: 45,736 individuals | 19.5-mg LNG IUD: 45,736 individuals
  • Dispensation of a 52-mg LNG IUD, compared to a 19.5-mg LNG IUD, was associated with a significantly increased use of an antidepressant within 2 years
    • 52-mg: 4.0%
    • 19.5-mg: 3.6%
    • aOR 1.13 (95% CI, 1.05 to 1.21)
  • The association with antidepressant use persisted in females without a medical history
    • 52-mg: 3.8%
    • 19.5-mg: 3.3%
    • aOR 1.19 (95% CI, 1.09 to 1.31)
  • There was no significant difference between the groups in the use of other psychotropic drugs
    • Anxiolytics
      • 52-mg: 5.2%
      • 19.5-mg: 4.9%
      • aOR 1.05 (95% CI 0.99 to 1.12)
    • Hypnotics
      • 52-mg: 2.9%
      • 19.5-mg: 2.6%
      • aOR 1.09 (95% CI, 0.99 to 1.19)
  • Individuals <25 years who were using a 52-mg LNG IUD were at higher risk of using hypnotics
    • 52-mg: 3.2%
    • 19.5-mg: 2.2%
    • aOR 1.61 (95% CI, 1.04 to 2.48)
  • There were no other significant associations between LNG IUD dose and psychotropic drug use for other age categories

CONCLUSION:

  • Compared to the 19.5-mg LNG IUD, the 52-mg IUD was associated with a small but significant increase in the risk of new antidepressant use
  • These differences in antidepressant use by IUD dose are unlikely to be clinically significant on an individual level
  • The authors state

The lack of a strong dose-response relationship may suggest that levonorgestrel, and thereby serum progestin, does not markedly cause mood disturbances in females using a levonorgestrel intrauterine system 

Learn More – Primary Sources:

Association Between Doses of Levonorgestrel Intrauterine Systems and Subsequent Use of Psychotropic Drugs in France

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does Risk for Ectopic Pregnancy Risk Differ Based on Hormonal IUD Dose?
Are Hormonal Contraceptives Associated with Increased Risk for Depression?
Meta-analysis: What Misconceptions Do Adolescents Have About LARCs?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site